AI assistant
GlaxoSmithKline PLC Director's Dealing 2026
5262_dirs_2026-02-11_515a3a0b-bfe4-4190-a6fe-4388ece69793.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 6429S
GSK PLC
11 February 2026
GSK plc (the 'Company')
Vesting of Conditional Share Awards under the Share Value Plan and Sale of Ordinary Shares and American Depositary Shares
This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') of conditional awards over Ordinary Shares and American Depositary Shares ('ADS') made in 2023 under the GSK Share Value Plan and the subsequent sale of Ordinary Shares and ADS to meet tax liabilities. The awards, which were conditional on continued employment with the GSK group, vested on 9 February 2026.
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Lynn Baxter | |||
| b) | Position/status | President, Europe | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,050 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Lynn Baxter | |||
| b) | Position/status | President, Europe | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £21.9082 | 4,084 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mike Crichton | |||
| b) | Position/status | President, International | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,050 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mike Crichton | |||
| b) | Position/status | President, International | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £21.9082 | 3,920 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Maya Martinez-Davis | |||
| b) | Position/status | President, US | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADS') ISIN: US37733W2044 |
|||
| b) | Nature of the transaction | The vesting of ADS awarded in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 10,658 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Maya Martinez-Davis | |||
| b) | Position/status | President, US | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADS') ISIN: US37733W2044 |
|||
| b) | Nature of the transaction | The sale of ADS to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $59.0729 | 2,789 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Nina Mojas | |||
| b) | Position/status | President, Global Product Strategy | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 23,120 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Nina Mojas | |||
| b) | Position/status | President, Global Product Strategy | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £21.9082 | 6,104 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Victoria Whyte | |||
| b) | Position/status | SVP & Company Secretary | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,050 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Victoria Whyte | |||
| b) | Position/status | SVP & Company Secretary | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £21.9082 | 4,724 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Neil Falkingham | |||
| b) | Position/status | PCA of Lynn Baxter (President, Europe) | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The vesting of Ordinary Shares awarded in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,050 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | N/A |
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Neil Falkingham | |||
| b) | Position/status | PCA of Lynn Baxter (President, Europe) | |||
| c) | Initial notification/ amendment |
Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 |
|||
| b) | Nature of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2023 under the Company's Share Value Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £21.9082 | 4,373 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
| Aggregated volume Price | |||||
| e) | Date of the transaction | 2026-02-09 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) |
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHSFDFLFEMSEFE